ArticleDiabetologia2014
A dysglycaemic effect of statins in diabetes: relevance to clinical practice?
Article in Diabetologia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 17 citations in OpenAlex.
- The Impact of Age on Statin-Related Glycemia: A Propensity Score-Matched Cohort Study in Korea.Healthcare (Basel, Switzerland) · 2022Article
- Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea.Cardiovascular diabetology · 2018Observational
- Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA Study.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2017Article
- Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2016Article
- The diabetogenic action of statins - mechanisms and clinical implications.Nature reviews. Endocrinology · 2016Review
- Alternative Interventions to Prevent Oxidative Damage following Ischemia/Reperfusion.Oxidative medicine and cellular longevity · 2016Review
- Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this issue of the journal, Erqou and colleagues (DOI 10.1007/s00125-014-3374-x ) report, in a systematic review and meta-analysis of randomised trials, a very modest (1.3 mmol/mol or 0.12%) albeit significant increase in HbA1c in patients with diabetes treated with statins, compared with control. Here, we discuss the clinical relevance of the findings. Given the overwhelming benefit of statins on cardiovascular outcomes in diabetes, current guidelines recommending statins for primary prevention in type 2 diabetes should not change, and any effect on microvascular risk is likely to be minimal. Of course, all patients recommended for statin treatment, whether they have diabetes or not, should now be warned of a slight potential for dysglycaemia on starting statins, but at the same time they should be told that very modest lifestyle improvement will help offset this dysglycaemia risk. Finally, we remind colleagues that nearly all drugs have side effects and we should not be surprised by this statin-dysglycaemia effect, which can be easily managed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.